US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
PLAINSBORO, N.J., May 24, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it will present at the following conferences in June:
- At 4:00PM ET on Wednesday, June 7, 2017, Mr. Peter Arduini, president and chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City. This presentation will be webcast.
- At 11:00AM ET on Wednesday, June 21, 2017, Mr. Robert T. Davis, Jr. president of Orthopedics & Tissue Technologies, will present at the 2017 JMP Securities Life Sciences Conference in New York City. This presentation will not be webcast.
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Michael Beaulieu (609) 750-2827 [email protected]
